Bahrain has approved the emergency use of AstraZeneca's anti-COVID drug, the state news agency (BNA) reported on Sunday.
Bahrain has become the first country to authorize the drug, which will be limited to adults who suffer from immunodeficiency or who are taking immunosuppressants, as well as individuals with occupations that put them at risk of transmission, the news agency quoted the National Health Regulatory Authority as saying.
The decision follows the evaluation of data provided by AstraZeneca, and carried out by the NHRA's Pharmaceutical Products Regulation department, it said.
EVUSHELD is made from a mixture of two antibodies, which achieved a “statistically significant decrease in cases of acute or fatal COVID-19 infection” in patients who were not hospitalized and those with symptoms ranging from mild to moderate, BNA said.
